News from valeant pharmaceuticals international, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 18, 2018, 08:00 ET FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion

Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete...

Jun 01, 2018, 04:15 ET Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it has entered into a Fourth Amended &...

May 31, 2018, 08:30 ET Salix To Highlight New Clinical Data During Digestive Disease Week

Salix Pharmaceuticals, a leading specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal disorders and a...

May 17, 2018, 07:15 ET Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International...

May 17, 2018, 05:00 ET Valeant Announces Pricing Of Private Offering Of Notes

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International...

May 15, 2018, 08:00 ET Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance and ...

May 10, 2018, 08:30 ET Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer,...

May 10, 2018, 07:00 ET Valeant To Seek Refinancing of its Existing Credit Agreement

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it is seeking to amend and restate its...

May 08, 2018, 07:00 ET Valeant Will Become Bausch Health Companies Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company" or "we") today announced that the Company will change its...

May 08, 2018, 07:00 ET Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance

Outperformed Expectations in the First Quarter of 2018 Revenues of $1.995 Billion GAAP Net Loss of $2.693 Billion GAAP Cash Flow from Operations of...

May 03, 2018, 08:00 ET Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance,...

May 02, 2018, 08:00 ET Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that the U.S. District Court for the...

Apr 27, 2018, 08:00 ET Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting

Bausch + Lomb, a leading global eye health company, and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), announced...

Apr 12, 2018, 04:15 ET Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned...

Apr 12, 2018, 02:51 ET Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that the Arbitral Tribunal issued a decision (rendered on April 9, 2018)...

Apr 11, 2018, 08:00 ET Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery

Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), will present ...

Apr 10, 2018, 07:33 ET Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") announced today the expiration of the cash tender offers (the "Tender...

Apr 09, 2018, 07:00 ET Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology

Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC (NYSE/TSX: VRX), today announced that the Journal of the American...

Apr 06, 2018, 08:00 ET Valeant Will Release First-Quarter 2018 Financial Results On May 8

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") will release its first-quarter 2018 financial results on Tuesday, May 8, 2018....

Mar 26, 2018, 07:00 ET Valeant and One of its Subsidiaries Announce Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the...

Mar 12, 2018, 07:43 ET Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Valeant Pharmaceuticals International ("VPI," and together with...

Mar 12, 2018, 07:40 ET Valeant Announces Pricing of Private Offering of Senior Notes

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") announced today that Valeant Pharmaceuticals...

Mar 12, 2018, 07:31 ET Valeant Announces Launch Of Private Offering Of Senior Notes

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") announced today that Valeant Pharmaceuticals...

Mar 12, 2018, 07:30 ET Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Valeant Pharmaceuticals International ("VPI," and together with...

Mar 08, 2018, 08:00 ET Valeant To Participate At The 2018 Barclays Global Healthcare Conference

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive...